Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Efficacy and safety of ensartinib in the treatment of non-small cell lung cancer: A systematic review of clinical trials.
Trushdeep Agrawal
Published: 202510.1177/10781552251387058
Abstract
ObjectiveAnaplastic lymphoma kinase (ALK) rearrangements are one of the key therapeutic targets in non-small cell lung cancer (NSCLC). Ensartinib, a second-generation ALK tyrosine kinase inhibitor (TKI), was recently approved by the FDA for the treat…
Preview only. Read the full abstract at the source